Shilpa Medicare: Shilpa Medicare Limited Unit IV Jadcherla Telangana Facility Has Received Health Canada GMP Approval | Value Research

Best Funds for 2023: Handpicked Mutual Funds to build a winning portfolio.
(₹1,499 ₹999)

Buy Now Buy Now right-arrow

Shilpa Medicare: Shilpa Medicare Limited Unit IV Jadcherla Telangana Facility Has Received Health Canada GMP Approval

This is to inform you that the Companys finished dosage form manufacturing facility Unit IV situated at Pharma SEZ Jadcherla Telangana has received Health Canada GMP approval for the inspection conducted from September 12 2022 to September 16 2022.The facility is involved in manufacturing packaging labelling and testing of finished dosage forms (sterile injections and oral solids) for the treatment of cancer and adjuvant therapy. This GMP approval will allow the company for the commercial distribution of products in Canada and enable new application submissions to Health Canada.This approval reaffirms the companys focused efforts to maintain the GMP status up to the standards of global regulatory authorities.This is for your information and doing the needful

Click here to view PDF


Other Categories